ALLUVI: A DEEP EXPLORATION INTO RETATRUTIDE'S POTENTIAL

Alluvi, initially dubbed LY3414901, represents a exciting advancement in obesity management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist shows remarkable effectiveness in early trial data, with substantial reduction in